National Service Delivery Guidelines for Cervical Cancer Prevention and Control

Objectives

Malawi’s cervical cancer prevention and control guidelines provide a public-health framework for maximising evidence-based services, reducing cervical cancer deaths, and supporting national planning, implementation, monitoring, evaluation and programme expansion.[1][2][3]The framework covers primary prevention, screening and treatment of pre-cancer, diagnosis and treatment of invasive cancer, follow-up, palliative care, referral, community mobilisation, education and management of sexually transmitted infections relevant to screening.[4][5][6]

• Prevent human papillomavirus infection through vaccination of girls aged 9 to 14 years before sexual exposure, alongside safer sexual practices, condom promotion or provision, fewer sexual partners, male circumcision where appropriate, and tobacco avoidance.[7][8][9][10]
• Increase informed uptake of prevention services by engaging women aged 25 to 49 years, men, community leaders, survivors, women’s organisations, peers and hard-to-reach groups through respectful, culturally sensitive education and counselling.[11][12][13][14]
• Expand early detection through population-based screening, generally beginning at age 25, with visual inspection with acetic acid as the principal widely available test and Pap smear or human papillomavirus testing used in specified circumstances.[15][16][17]
• Provide timely treatment for eligible pre-cancerous lesions, preferably through a screen-and-treat model that reduces loss to follow-up, while referring suspected cancer for diagnostic confirmation and specialist management.[15][17][18]
• Prioritise women living with HIV through integration with HIV care, more frequent screening and close post-treatment follow-up because of elevated risks of persistent infection, progression and recurrence.[19][20][21]
• Deliver stage-appropriate cancer treatment, aiming to cure disease where possible and otherwise reduce disease burden, symptoms and suffering through surgery, radiotherapy, chemotherapy, supportive care and palliative care.[22][23][24][25]

Implementation

Implementation is designed for delivery across health facilities by health surveillance assistants, nurses, midwives, clinical officers, medical doctors, gynaecologists, health managers and specialist teams according to competency and service level.[1][26][27][28]The Ministry of Health and Population leads national implementation, supported by its Reproductive Health Directorate, the National Cervical Cancer Task Force, service providers, policymakers, technical and implementing partners.[1][2]

• Integrate screening with HIV and antiretroviral therapy clinics, family-planning, sexually transmitted infection, gynaecology, reproductive-health and other suitable services, using cross-training, shared clinic space and coordinated client flow to broaden coverage and improve efficiency.[3][29][30]
• Assess readiness before opening or expanding screening sites, covering infrastructure, competent staff, equipment, medicines and supplies, guidelines, registers, community mobilisation, supervision and referral arrangements.[3][29]
• Train and certify providers through competency-based programmes covering screening, ablative treatment, infection prevention and control, monitoring and evaluation, reporting and defined health-worker responsibilities; supplement training with mentorship, supportive supervision and continuous professional development.[31][32]
• Deliver community mobilisation beyond facilities through community health workers, peer communication, mobile screening units or vaccine brigades, and media including radio, television, posters, pamphlets and social media.[12][13]
• Provide confidential counselling, informed consent and client-centred decision-making, including explanation of results, treatment options, follow-up requirements, privacy protections and barriers such as transport, finances or partner support.[33][21][34]
• Apply differentiated screening intervals, with VIA every three years for HIV-negative women and every two years for women living with HIV; following treatment, conduct annual VIA for three years before return to routine screening after consecutive negative results.[15][17]
• Provide cryotherapy and thermocoagulation as outpatient ablative treatment where eligibility criteria are met, and use large loop excision of the transformation zone or cold knife conisation where tissue diagnosis, lesion characteristics or clinical circumstances require excision.[35][18][36]
• Refer suspected invasive cancer for biopsy, histopathological confirmation, staging and tertiary-level multidisciplinary treatment; maintain follow-up, symptom management and palliative care as close to home as possible where cancer-directed treatment is no longer beneficial.[27][22][37][25]
• Use standard referral forms, referral registers, receiving-facility feedback, client tracing and monthly facility reviews to reduce missed appointments and strengthen referral performance.[38][39]
• Collect, analyse and use data at site, district, regional and national levels; standardise registers and reports, define indicator numerators, denominators and monitoring frequencies, and use continuous quality improvement and plan-do-study-act cycles to improve performance.[3][40][31]
• Maintain quality assurance for screening, treatment, laboratories, provider certification, referral waiting times and the completeness and timeliness of data, with timely feedback from higher levels of the health system.[41][16][31]

Monitoring & Evaluation

Monitoring, evaluation and quality assurance are positioned as core management functions for Malawi’s cervical cancer control programme, intended to improve effectiveness, efficiency, service quality, client satisfaction, safety and health outcomes.[3][40]Data should be collected, analysed and used at service-delivery, district, regional and national levels, with site-level data supporting local quality improvement and Ministry of Health and Population processes supporting planning and decision-making.[3][40]

• Develop a monitoring and evaluation framework containing core performance and impact indicators, including measures of effects on cervical cancer incidence and mortality, with defined numerators, denominators and monitoring frequencies.[40][31]
• Use continuous monitoring to identify implementation progress, outputs, schedules, deficiencies and obstacles, and use evaluation to assess effectiveness, efficiency, impact, errors and transferable lessons.[40]
• Standardise paper visual inspection with acetic acid registers, define reportable data, conduct regular facility-level data reviews, and submit consistent reports to the Ministry of Health and Population for central tracking and regional comparison.[31]
• Include visual inspection with acetic acid results from antiretroviral therapy clinics in the same reporting system as other screening sites, and use electronic medical records with care prompts where available.[31]
• Establish continuous quality improvement across screen-and-treat sites, treatment facilities, laboratories, training programmes, and monitoring, evaluation and data-management systems.[31]
• Develop standards and standard operating procedures covering screening certification and monitoring, treatment availability and referral waiting times, laboratory procedures and quality assurance, and data completeness and timeliness.[31]
• Evaluate standards at facility and higher levels, provide timely feedback, and adapt practice through the plan-do-study-act cycle.[31]
• Use periodic mentorship, supportive supervision and continuous professional development to maintain provider competence; digital images may support supervision or quality assurance where confidentiality and ethical approvals permit.[32]

Clinical documentation and follow-up mechanisms supplement programme monitoring. Providers are required to record screening results in the client health passport and cervical cancer screening register, document treatment and laboratory specimens, and provide written instructions on subsequent care.[42][43][44]Colposcopy, biopsy, LLETZ and cold knife conisation records should capture findings, procedures, specimen details and overall clinical impressions, while laboratory requisition forms support histopathology review.[45][46][47]

• Track human papillomavirus vaccine doses carefully, particularly for girls living with HIV who require a three-dose schedule that may differ from the standard school-based schedule.[9]
• Monitor vaccine safety by observing recipients for 15 minutes after vaccination because fainting can occur.[48]
• Apply quality control and quality assurance to visual inspection with acetic acid, recognising that the test is subjective and depends on provider skill and experience.[41]
• Track adherence to screening intervals, including two-yearly screening for women living with HIV, three-yearly screening for HIV-negative women, and annual screening for three years after treatment.[17]
• Maintain a functioning quality-control and quality-improvement programme for Pap smear services to reduce delays and loss to follow-up.[16]
• Monitor treatment safety and follow-up, including cryotherapy duration and adequate freezing, post-treatment complications, histopathology review, cervical healing and repeat screening.[49][46][50]
• Monitor chemotherapy and radiotherapy through blood counts and liver and renal function tests to identify or prevent infection and other treatment-related co-morbidities.[51]
• Review referrals through register summaries and monthly facility reviews, examining avoidable or inappropriate referrals, feedback, outstanding follow-up, and the timeliness and completeness of information exchange.[39]
• Use referral statistics and periodic referral analysis to identify system problems, training needs and operational improvements, and to adapt protocols as service capacity changes.[25][39][52]

Several detailed programme elements remain unspecified in the supplied material, including a complete indicator set, reporting timetable, surveillance architecture, evaluation schedule and formal accountability or enforcement arrangements.[16][17][40]

Costing & Financing

The guidance identifies substantial resource requirements for comprehensive cervical cancer prevention and control, but does not provide a programme budget, costed implementation plan, quantified funding gap, financing allocation, resource-mobilisation strategy or economic assumptions.[29][40][31]Guideline development received financial support from the United States Centers for Disease Control and Prevention, while an earlier Cooperative Agreement is identified as 5 NU2GGH001471-04.[53][1]

• Provide infrastructure, equipment, medicines, supplies, trained personnel, referral networks and supervisory support before opening new screening sites.[29]
• Invest in surgical infrastructure and provider training to meet increased treatment demand, particularly for gynaecologists.[29]
• Recognise that visual inspection with acetic acid requires relatively limited equipment and is lower cost than other screening methods, supporting its use as the principal screening method in Malawi.[41][16]
• Provide equipment and specialised training for human papillomavirus DNA testing, Pap smear services, colposcopy, biopsy, excisional treatment, cold knife conisation and histopathology.[54][36][55]
• Recognise that population-based Pap smear screening is resource-intensive and that colposcopy requires expensive equipment and specialised training.[16]
• Account for recurring carbon dioxide or nitrous oxide supply and transport costs for cryotherapy, despite cryotherapy being less expensive than excisional procedures.[56]
• Prioritise available human papillomavirus vaccines for girls at risk because the vaccines are described as costly.[48]
• Expand vaccination to older girls or boys only after adequate coverage of the primary target group and where financially sustainable resources are available.[9]
• Consider clients’ and families’ out-of-pocket costs, ability to travel and need for social support when planning cancer treatment.[23]
• Use service integration to improve efficiency in human and financial resource use, including integration of screening with HIV, antiretroviral therapy, family-planning, sexually transmitted infection and other reproductive-health services.[29][32][30]

Radiotherapy capacity was anticipated through the national cancer centre at Kamuzu Central Hospital in Lilongwe, expected to open in mid-to-late 2019, but the material provides no associated capital or operating cost.[57][24][29]Palliative and referral services are expected to provide affordable, cost-effective care as close to home as possible, without specifying expenditure or funding sources.[25]